Share Name Share Symbol Market Type Share ISIN Share Description
Medici Bioventures LSE:MEB London Ordinary Share GB00B06JMG05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p - - - - - - - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0.00

Medici Share Discussion Threads

Showing 1 to 7 of 25 messages
Chat Pages: 1
DateSubjectAuthorDiscuss
04/8/2007
10:15
shares in tony barton niplads start trading in sept lets hope they go well
jammytass
09/7/2007
18:38
Give me hope Joanna
5willie
29/6/2006
18:20
Medici Bioventures Statement re. Suspension RNS Number:8254A Medici Bioventures PLC 03 April 2006 Medici Bioventures plc Statement re suspension The Directors announce that, in accordance with the guidance note to AIM Rule 8, Medici Bioventures plc ("the Company") has been suspended pursuant to AIM Rule 40. Since publication of the Company's interim results to 31 December 2005, the Directors have continued to review a number of investment opportunities but none have been viewed suitable or met their investment strategy. The Directors will continue to review opportunities with the objective of completing a reverse takeover in accordance with the requirements of the AIM Rules. In accordance with the guidance note to AIM Rule 8, trading in the Company's shares on AIM will be cancelled pursuant to AIM Rule 41 if the Company does not complete a reverse takeover within 6 months of its suspension. Anthony Barton Chairman This information is provided by RNS The company news service from the London Stock Exchange
bitterlemontart
29/6/2006
18:15
Medici Bioventures Suspension -Medici Bioventure RNS Number:7748A AIM 03 April 2006 NOTICE (222) 03/04/2006 7:00am TEMPORARY SUSPENSION OF TRADING ON AIM MEDICI BIOVENTURES PLC Trading on AIM for the under-mentioned securities has been temporarily suspended from 03/04/2006 7:00am pursuant to AIM Rule 8. Ordinary Shares of 0.1p each (B06JMG0)(GB00B06JMG05) fully paid If you have any queries relating to the above, please contact the nominated adviser on 020 7710 7400. Ref: AIMNOT222 This information is provided by RNS The company news service from the London Stock Exchange
bitterlemontart
29/6/2006
18:10
Medici Bioventures Interim Results RNS Number:6292T Medici Bioventures PLC 03 November 2005 Medici Bioventures plc Interim Financial Statements For the six months ended 31 August 2005 Chairman's Statement On behalf of the board of Medici Bioventures plc, I am pleased to present the Company's results for the six months ended 31 August 2005. Medici Bioventures plc continues to investigate investment opportunities in the life sciences sectors. Medici Bioventures plc equity interest in any proposed investment may range from a minority position to 100% ownership. The proposed investments may be either quoted or unquoted and may be in companies, partnerships, joint ventures or direct interests in life science projects. Whilst it is likely that the investments will be made in development stage undertakings, the Directors may decide that the Company should invest in commercialised assets. The Company's focus is on life science opportunities in the United Kingdom where the Directors believe that a number of opportunities exist to acquire interests in suitable projects. The Company will also review opportunities in Europe and Australasia. The Company will look to acquire holdings directly or in emergent life science projects or companies. The Directors are experienced in evaluating acquisition and investment prospects, quoted and unquoted, both in the UK and overseas and are able to call on independent expertise in the sector. The Directors have reviewed a number of investment opportunities during the reporting period but none to date have been viewed suitable or met our investment strategy. Anthony Barton Chairman
bitterlemontart
29/6/2006
18:05
Medici Bioventures Interim Results RNS Number:6292T Medici Bioventures PLC 03 November 2005 Medici Bioventures plc Interim Financial Statements For the six months ended 31 August 2005 Chairman's Statement On behalf of the board of Medici Bioventures plc, I am pleased to present the Company's results for the six months ended 31 August 2005. Medici Bioventures plc continues to investigate investment opportunities in the life sciences sectors. Medici Bioventures plc equity interest in any proposed investment may range from a minority position to 100% ownership. The proposed investments may be either quoted or unquoted and may be in companies, partnerships, joint ventures or direct interests in life science projects. Whilst it is likely that the investments will be made in development stage undertakings, the Directors may decide that the Company should invest in commercialised assets. The Company's focus is on life science opportunities in the United Kingdom where the Directors believe that a number of opportunities exist to acquire interests in suitable projects. The Company will also review opportunities in Europe and Australasia. The Company will look to acquire holdings directly or in emergent life science projects or companies. The Directors are experienced in evaluating acquisition and investment prospects, quoted and unquoted, both in the UK and overseas and are able to call on independent expertise in the sector. The Directors have reviewed a number of investment opportunities during the reporting period but none to date have been viewed suitable or met our investment strategy. Anthony Barton Chairman
bitterlemontart
29/6/2006
18:00
Medici Bioventures Statement re. Suspension RNS Number:8254A Medici Bioventures PLC 03 April 2006 Medici Bioventures plc Statement re suspension The Directors announce that, in accordance with the guidance note to AIM Rule 8, Medici Bioventures plc ("the Company") has been suspended pursuant to AIM Rule 40. Since publication of the Company's interim results to 31 December 2005, the Directors have continued to review a number of investment opportunities but none have been viewed suitable or met their investment strategy. The Directors will continue to review opportunities with the objective of completing a reverse takeover in accordance with the requirements of the AIM Rules. In accordance with the guidance note to AIM Rule 8, trading in the Company's shares on AIM will be cancelled pursuant to AIM Rule 41 if the Company does not complete a reverse takeover within 6 months of its suspension. Anthony Barton Chairman This information is provided by RNS The company news service from the London Stock Exchange
bitterlemontart
Chat Pages: 1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161206 05:44:52